Autoregulation of kinase dephosphorylation by ATP binding to AGC protein kinases

Cell Cycle

Volumn 11, Issue 3, 2012, Pages 475-478

  Chan, Tung O ^a,c   Pascal, John M ^a,c   Armen, Roger S ^b   Rodeck, Ulrich ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Activation loop phosphorylation; Dephosphorylation; Inhibitors hijacking kinase activation; Phosphatase resistance; PKA; PKB; PKC

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; A 443654; ADENOSINE TRIPHOSPHATE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE C; UNCLASSIFIED DRUG;

AUTOREGULATION; CATALYSIS; HUMAN; IN VITRO STUDY; MUTATIONAL ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 84857226839     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.3.19059     Document Type: Review

References (32)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912-34; PMID:12471243; http://dx.doi.org/10.1126/science.1075762.
2. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002; 109:275-82; PMID:12015977; http://dx.doi.org/10.1016/S0092-8674(02)00741- 9.
3. Kannan N, Haste N, Taylor SS, Neuwald AF. The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. Proc Natl Acad Sci USA 2007; 104:1272-7; PMID:17227859; http://dx.doi.org/10. 1073/pnas.0610251104.
4. Takimura T, Kamata K, Fukasawa K, Ohsawa H, Komatani H, Yoshizumi T, et al. Structures of the PKC-iota kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533-551 in the C-terminal tail and their roles in ATP binding. Acta Crystallogr D Biol Crystallogr 2010; 66:577-83; PMID:20445233; http://dx.doi.org/10.1107/ S0907444910005639.
5. Nolen B, Taylor S, Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 2004; 15:661-75; PMID:15350212; http://dx.doi.org/10.1016/j.molcel.2004.08.024.
6. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 2002; 9:940-4; PMID:12434148; http://dx.doi.org/ 10.1038/nsb870.
7. Yang J, Cron P, Thompson V, Good VM, Hess D, Hemmings BA, et al. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 2002; 9:1227-40; PMID:12086620; http://dx.doi.org/10.1016/S1097-2765(02)00550-6.
8. Calleja V, Laguerre M, Larijani B. 3-D structure and dynamics of protein kinase B-new mechanism for the allosteric regulation of an AGC kinase. J Chem Biol 2009; 2:11-25; PMID:19568789; http://dx.doi. org/10.1007/s12154-009-0016-8.
9. Wu WI, Voegtli WC, Sturgis HL, Dizon FP, Vigers GP, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One 2010; 5:12913; PMID:20886116; http://dx.doi.org/10.1371/journal.pone.0012913.
10. Chan TO, Zhang J, Rodeck U, Pascal JM, Armen RS, Spring M, et al. Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Proc Natl Acad Sci USA 2011; 108:1120- 7; PMID:22031698; http://dx.doi.org/10.1073/ pnas.1109879108.
11. Davies TG, Verdonk ML, Graham B, Saalau-Bethell S, Hamlett CC, McHardy T, et al. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J Mol Biol 2007; 367:882-94; PMID:17275837; http://dx.doi.org/10.1016/ j.jmb.2007.01.004.
12. Andersen MD, Shaffer J, Jennings PA, Adams JA. Structural characterization of protein kinase A as a function of nucleotide binding. Hydrogen-deuterium exchange studies using matrix-assisted laser desorption ionization-time of flight mass spectrometry detection. J Biol Chem 2001; 276:14204-11; PMID:11278927.
13. Shaffer J, Adams JA. Detection of conformational changes along the kinetic pathway of protein kinase A using a catalytic trapping technique. Biochemistry 1999; 38:12072-9; PMID:10508411; http://dx.doi.org/10.1021/ bi991109q.
14. Khavrutskii IV, Grant B, Taylor SS, McCammon JA. A transition path ensemble study reveals a linchpin role for Mg(2+) during rate-limiting ADP release from protein kinase A. Biochemistry 2009; 48:11532- 45; PMID:19886670; http://dx.doi.org/10.1021/bi901475g.
15. Han EK, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 2007; 26:5655-61; PMID:17334390; http://dx.doi.org/10.1038/ sj.onc.1210343.
16. Levy DS, Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009; 113:1723-9; PMID:19064730; http://dx.doi.org/10.1182/blood-2008-02-137737.
17. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005; 4:977-86; PMID:15956255; http://dx.doi.org/10.1158/1535- 7163.MCT-05-0005.
18. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008; 68:2366-74; PMID:18381444; http://dx.doi.org/10.1158/0008-5472.CAN-07-5783.
19. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, et al. Inhibitor hijacking of Akt activation. Nat Chem Biol 2009; 5:484-93; PMID:19465931; http://dx.doi.org/10.1038/nchembio.183.
20. Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 1990; 59:971- 1005; PMID:2165385; http://dx.doi.org/10.1146/ annurev.bi.59.070190. 004543.
21. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999; 68:965-1014; PMID:10872470; http://dx.doi.org/10.1146/annurev.biochem.68.1.965.
22. Parekh DB, Ziegler W, Parker PJ. Multiple pathways control protein kinase C phosphorylation. EMBO J 2000; 19:496-503; PMID:10675318; http://dx.doi. org/10.1093/emboj/19.4.496.
23. Humphries KM, Deal MS, Taylor SS. Enhanced dephosphorylation of cAMP-dependent protein kinase by oxidation and thiol modification. J Biol Chem 2005; 280:2750-8; PMID:15533936; http://dx.doi. org/10.1074/jbc.M410242200.
24. Srivastava J, Goris J, Dilworth SM, Parker PJ. Dephosphorylation of PKCdelta by protein phosphatase 2Ac and its inhibition by nucleotides. FEBS Lett 2002; 516:265-9; PMID:11959144; http://dx.doi. org/10.1016/S0014-5793(02)02500- 0.
25. Cameron AJ, Escribano C, Saurin AT, Kostelecky B, Parker PJ. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase Activity. Nat Struct Mol Biol 2009; 16:624-30; PMID:19465915; http://dx.doi.org/10.1038/ nsmb.1606.
26. Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, Sebolt-Leopold J. A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 2005; 7:336-47; PMID:15967111; http:// dx.doi.org/10.1593/neo.04532.
27. Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 2007; 6:138-46; PMID:17237274; http://dx.doi. org/10.1158/1535-7163.MCT-06-0436.
28. Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with upregulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2009; 329:1063- 70; PMID:19258520; http://dx.doi.org/10.1124/ jpet.108.147306.
29. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase And Raf proteins. Cancer Res 2008; 68:6145-53; PMID:18676837; http://dx.doi.org/10.1158/0008-5472.CAN-08-1430.
30. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004; 11:1192-7; PMID:15543157; http://dx.doi. org/10.1038/nsmb859.
31. Fischmann TO, Smith CK, Mayhood TW, Myers JE, Reichert P, Mannarino A, et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 2009; 48:2661- 74; PMID:19161339; http://dx.doi.org/10.1021/ bi801898e.
32. Bossemeyer D, Engh RA, Kinzel V, Ponstingl H, Huber R. Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J 1993; 12:849-59; PMID:8384554.